Tner A, Hodak E, David M, Sandbank M: The appearance of Kaposi sarcoma during corticosteroid

Tner A, Hodak E, David M, Sandbank M: The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer 1993, 72(5):1779-83. Guo WX, Antakly T, Cadotte M, Kachra Z, Kunkel L, Masood R, Gill P: Expression and cytokine regulation of glucocorticoid receptors in Kaposi’s sarcoma. Am J Pathol 1996, 148(6):1999-2008. Guo WX, Antakly T: AIDS-related Kaposi’s sarcoma: evidence for direct stimulatory effect of glucocorticoid on cell proliferation. Am J Pathol 1995, 146(3):727-34. Trattner A, Hodak E, David M, Neeman A, Sandbank M: Kaposi’s sarcoma with visceral involvement after intraarticular and epidural injections of corticosteroids. J Am Acad Dermatol 1993, 29(5 Pt 2):890-4. Bruet A, Mahe A, Sei JF, Mathe C, Felsenheld C, Lechevalier L, Fendler JP: Kaposi’s sarcoma complicating long-term corticotherapy for severe asthma. Rev Med Interne 1990, 11(4):322-4. Rybojad M, Borradori L, Verola O, Zeller J, Puissant A, Morel P: NonAIDS-associated Kaposi’s sarcoma (classical and endemic African types):treatment with low doses of recombinant interferon-alpha. J Invest Dermatol 1990, 95(6 Suppl):176S-179S. Shimizu S, Tanaka M, Niizeki H, Miyakawa S, Ishiko A, Shimizu H: Classic (non-AIDS-related) Kaposi’s sarcoma in a Japanese patient, successfully treated with alpha-2b-interferon. Br J Dermatol 1995, 133(2):332-4. Aldenhoven M, Barlo NP, Sanders CJ: Therapeutic strategies for epidemic Kaposi’s sarcoma. Int J STD AIDS 2006, 17(9):571-8. Campistol JM, Guti rez-Dalmau A, Torregrosa JV: Conversion to sirolimus: a CyclopamineMedChemExpress Cyclopamine successful treatment for posttransplantation Kaposi’s sarcoma. Transplantation 2004, 77(5):760-2. Zmonarski SC, Boratynska M, Rabczynski PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28499442 J, Kazimierczak K, Klinger M: Regression of Kaposi’s sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 2005, 37(2):964-6.Pre-publication historyThe pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2369/8/6/prepubAuthors’ contributionsThe three authors of this manuscript: Patricia Volkow, Juan W Zinser, Ricardo Correa-Rotter are treating physicians of the patient reported. All of them have participated in the discussion and writing of the submitted manuscript.
Rostoker et al. BMC Nephrology 2011, 12:58 http://www.biomedcentral.com/1471-2369/12/RESEARCH ARTICLEOpen AccessModulation of oxidative stress and microinflammatory status by colloids in refractory dialytic hypotensionGuy Rostoker1*, Mireille Griuncelli1, Christelle Loridon1, Thomas Bourlet1, Eric Illouz2 and Abbes BenmaadiAbstractBackground: Intradialytic hypotension may adversely affect the outcome of chronic hemodialysis. Therapeutic albumin has powerful anti-oxidant and anti-inflammatory properties. We have recently shown that systematic colloid infusion during hemodialysis sessions improves hemodynamic parameters in most dialysis hypotensionprone patients unresponsive to usual of preventive measures. We postulated that frequent hypotensive episodes may lead to a noxious inflammatory response mediated by oxidative stress induced by ischemia-reperfusion. The aim of this study was therefore to analyze the effect of 20 albumin and 4 gelatin infusions on oxidative stress and microinflammatory status in hypotension-prone patients unresponsive to usual preventive measures. Methods: Prospective cross-over study (lasting 20 weeks) of routine infusion of 200 ml of 20 albumin versus 200 ml of 4 gelatin in 10 patients with refractory intradialytic hypotension. We analyzed.